Crinetics Pharmaceuticals (Nasdaq: CRNX), a biopharma focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, was trading 14% higher by lunchtime Tuesday.
This followed the Californian company’s presentation of positive top-line results from PATHFNDR-2, the second of two Phase III studies evaluating the efficacy and safety of oral, once-daily investigational paltusotine for the treatment of acromegaly.
"Our team is actively preparing for a potential 2025 launch"PATHFNDR-2 was a randomized, double-blind, placebo-controlled 24-week treatment period, followed by an optional open-label extension study, evaluating paltusotine in 111 participants with acromegaly who were not pharmacologically treated.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze